Latest Action
Placed on the Union Calendar, Calendar No. 577.
12/24/2020 • House
Summary
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Reported to House • 12/24/2020
Enter your district to see how this bill affects your community
Topics & Subjects
Policy Area: Health
Administrative law and regulatory proceduresBusiness ethicsCivil actions and liabilityCompetition and antitrustDrug safety, medical device, and laboratory regulationFederal Trade Commission (FTC)Licensing and registrationsPublic participation and lobbying
CBO Cost Estimates (1)
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (8)
Party Breakdown
5
Democrats
3
Republicans
0
Independents
Sponsor
R[
Cosponsors (7)
R[
R[
R[
R[
RL
R[
Bill Journey
Originated in the House
Introduced
April 29, 2019
Committee Review
April 30, 2019
Ordered to be Reported by Voice Vote.
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law
Text Versions (2)
Reported in House12/24/2020
Introduced in House4/29/2019